Fig. 7 | Signal Transduction and Targeted Therapy

Fig. 7

From: Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity

Fig. 7

JOSD2 inhibitors abolish JOSD2 DUB activity. a Schematic illustration of JOSD2 inhibitors screening (top) and JOSD2 activity inhibition ratio of indicated compounds (n = 99) (bottom). Black dashed line indicates no inhibition on JOSD2 activity. 2 μM indicated compounds were incubated with GST-JOSD2 protein at 37 °C for 30 min and then subjected to in vitro ubiquitin-AMC assay. b Chemical structures of HY041004, HY04071 and HY032801. c 293FT cells transfected with LKB1-Flag, HA-Ub K6 and JOSD2-HA for 48 h were treated with indicated compounds for 4 h at concentration of 0.5 μM. IPs by Flag beads from cell lysates were subjected to IB. d 293T cells transfected with LKB1-Flag, STRAD-Myc, HA-Ub K6 and JOSD2-HA for 48 h were treated with indicated compounds for 4 h at concentration of 0.5 μM. IPs by Flag beads from cell lysates were subjected to IB. e PC-9 cells stably transfected with JOSD2-HA were treated with indicated compounds for 4 h at concentration of 0.5 μM and cell lysates were subjected to IB. f NCI-H358 cells were incubated with DMSO or 40 μM HY041004 and subjected to cellular thermal shift assay. Cell lysates were lysed by RIPA lysis buffer and then subjected to IB

Back to article page